+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Basal Cell Carcinoma Treatment Market Size, Share & Trends Analysis Report by Treatment Type (Surgery, Radiotherapy, Topical Chemotherapy, Intralesional Injections, Oral Medications, Chemical Peeling Treatment), Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 158 Pages
  • June 2024
  • Region: Global
  • Grand View Research
  • ID: 5982936
Description Jump to:
The global basal cell carcinoma treatment market size is anticipated to reach USD 5.93 billion by 2030, growing at a CAGR of 10.44% from 2024 to 2030. The market is primarily driven by the increasing prevalence of basal cell carcinoma and the rising geriatric population. The European Skin Cancer Foundation estimates that the incidence of basal cell carcinoma (BCC) is 50 to 80 new cases per 100,000 people in Europe and 250 cases per 100,000 people in Australia annually, with an increasing trend. The increase in the number of cancer cases can primarily be attributed to the growing overall & geriatric population and certain socioeconomic factors.

Technological advancement in the diagnosis and treatment of disease is anticipated to positively impact market growth. With advanced technologies, dermatologists can more accurately diagnose patients and effectively differentiate basal cell carcinoma from other skin lesions. For instance, in 2024, the U.S. FDA approved DermaSensor, an AI-powered light spectroscopy instrument for detecting skin cancer, including melanoma, single cell carcinoma (SCC), and basal cell carcinoma (BCC). This technique can help primary care clinicians identify patients who require rapid attention for a biopsy and specialist care, thereby alleviating high wait times and the shortage of dermatologists in certain places. The growing use of such diagnostic tools is expected to increase the diagnostic and treatment rates in the future, driving demand for medicines used for the treatment of basal cell carcinoma.

Furthermore, the increase in the geriatric population is driving the demand for treatment of BCC, including surgery, radiotherapy, topical chemotherapy, oral medications, and chemical peeling. The main cause of developing BCC is repeated exposure to Ultraviolet (UV) light. The elderly population has a higher chance of acquiring BCC than younger people as they have been exposed to UV rays for longer during their lifetime. Due to aging and reduced immune system function, UV radiation and other carcinogenic factors can break the DNA more easily, increasing the risk of skin cancer, especially BCC, in older persons. According to a study published in the Journal of Geriatric Oncology in 2023, over 100,000 patients with BCC are treated annually in their final year of life in the U.S. However, clinical practice guidelines hardly ever take age & comorbidities into account. Thus, a growing geriatric population is expected to drive market growth during the forecast period.

Basal Cell Carcinoma Treatment Report Highlights

  • The surgery segment held the largest revenue share of the market in 2023. This can be attributed to the increasing incidence and prevalence of disease and the high demand for surgery for treatment owing to high safety and efficacy.
  • In topical chemotherapy, the 5-fluorouracil (5-FU) segment held the largest share of the market in 2023. This can be attributed to the development and launch of a novel generic version of 5-fluorouracil (5-FU) to treat BCC patients.
  • North America dominated the market owing to factors such as advanced healthcare infrastructure, increasing prevalence of basal cell carcinoma, and favorable regulatory environment for R&D of novel products.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Treatment Type
1.2.2. Regional scope
1.2.3. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Treatment Type Outlook
2.2.2. Regional outlook
2.3. Competitive Insights
Chapter 3. Basal Cell Carcinoma Treatment Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of target diseases
3.2.1.2. Technological advancements
3.2.1.3. Rising geriatric population
3.2.2. Market restraint analysis
3.2.2.1. Adverse effects associated with treatment.
3.2.2.2. High cost of treatment
3.3. Basal Cell Carcinoma Treatment Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Basal Cell Carcinoma Treatment Market: Treatment Type Estimates & Trend Analysis
4.1. Global Basal Cell Carcinoma Treatment Market: Treatment Type Dashboard
4.2. Global Basal Cell Carcinoma Treatment Market: Treatment Type Movement Analysis
4.3. Global Basal Cell Carcinoma Treatment Market By Treatment Type, Revenue
4.4. Surgery
4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Mohs Surgery
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Surgical Excision
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Electrodesiccation and Curettage (ED&C)
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Radiotherapy (RT)
4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Intralesional Injections
4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Topical Chemotherapy
4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7.2. 5-fluorouracil (5-FU)
4.7.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7.3. Tirbanibulin (Klisyri)
4.7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7.4. Imiquimod (Zyclara)
4.7.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Oral Medications
4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.8.2. Vismodegib (Erivedge)
4.8.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.8.3. Sonidegib (Odomzo)
4.8.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Intravenous Medications
4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.10. Chemical Peeling Treatment
4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million).
Chapter 5. Basal Cell Carcinoma Treatment Market: Regional Estimates & Trend Analysis By Treatment Type
5.1. Regional Dashboard
5.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
5.3. North America
5.3.1. U.S.
5.3.1.1. Key country dynamics
5.3.1.2. Regulatory framework/ reimbursement structure
5.3.1.3. Competitive scenario
5.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
5.3.2. Canada
5.3.2.1. Key country dynamics
5.3.2.2. Regulatory framework/ reimbursement structure
5.3.2.3. Competitive scenario
5.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
5.3.3. Mexico
5.3.3.1. Key country dynamics
5.3.3.2. Regulatory framework/ reimbursement structure
5.3.3.3. Competitive scenario
5.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
5.4. Europe
5.4.1. UK
5.4.1.1. Key country dynamics
5.4.1.2. Regulatory framework/ reimbursement structure
5.4.1.3. Competitive scenario
5.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Germany
5.4.2.1. Key country dynamics
5.4.2.2. Regulatory framework/ reimbursement structure
5.4.2.3. Competitive scenario
5.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. France
5.4.3.1. Key country dynamics
5.4.3.2. Regulatory framework/ reimbursement structure
5.4.3.3. Competitive scenario
5.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4. Italy
5.4.4.1. Key country dynamics
5.4.4.2. Regulatory framework/ reimbursement structure
5.4.4.3. Competitive scenario
5.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
5.4.5. Spain
5.4.5.1. Key country dynamics
5.4.5.2. Regulatory framework/ reimbursement structure
5.4.5.3. Competitive scenario
5.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
5.4.6. Denmark
5.4.6.1. Key country dynamics
5.4.6.2. Regulatory framework/ reimbursement structure
5.4.6.3. Competitive scenario
5.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
5.4.7. Sweden
5.4.7.1. Key country dynamics
5.4.7.2. Regulatory framework/ reimbursement structure
5.4.7.3. Competitive scenario
5.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
5.4.8. Norway
5.4.8.1. Key country dynamics
5.4.8.2. Regulatory framework/ reimbursement structure
5.4.8.3. Competitive scenario
5.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Asia Pacific
5.5.1. Japan
5.5.1.1. Key country dynamics
5.5.1.2. Regulatory framework/ reimbursement structure
5.5.1.3. Competitive scenario
5.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
5.5.2. China
5.5.2.1. Key country dynamics
5.5.2.2. Regulatory framework/ reimbursement structure
5.5.2.3. Competitive scenario
5.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
5.5.3. India
5.5.3.1. Key country dynamics
5.5.3.2. Regulatory framework/ reimbursement structure
5.5.3.3. Competitive scenario
5.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
5.5.4. Australia
5.5.4.1. Key country dynamics
5.5.4.2. Regulatory framework/ reimbursement structure
5.5.4.3. Competitive scenario
5.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
5.5.5. South Korea
5.5.5.1. Key country dynamics
5.5.5.2. Regulatory framework/ reimbursement structure
5.5.5.3. Competitive scenario
5.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
5.5.6. Thailand
5.5.6.1. Key country dynamics
5.5.6.2. Regulatory framework/ reimbursement structure
5.5.6.3. Competitive scenario
5.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Latin America
5.6.1. Brazil
5.6.1.1. Key country dynamics
5.6.1.2. Regulatory framework/ reimbursement structure
5.6.1.3. Competitive scenario
5.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
5.6.2. Argentina
5.6.2.1. Key country dynamics
5.6.2.2. Regulatory framework/ reimbursement structure
5.6.2.3. Competitive scenario
5.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
5.7. MEA
5.7.1. South Africa
5.7.1.1. Key country dynamics
5.7.1.2. Regulatory framework/ reimbursement structure
5.7.1.3. Competitive scenario
5.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
5.7.2. Saudi Arabia
5.7.2.1. Key country dynamics
5.7.2.2. Regulatory framework/ reimbursement structure
5.7.2.3. Competitive scenario
5.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
5.7.3. UAE
5.7.3.1. Key country dynamics
5.7.3.2. Regulatory framework/ reimbursement structure
5.7.3.3. Competitive scenario
5.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
5.7.4. Kuwait
5.7.4.1. Key country dynamics
5.7.4.2. Regulatory framework/ reimbursement structure
5.7.4.3. Competitive scenario
5.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Competitive Landscape
6.1. Company/Competition Categorization
6.2. Participant Overview
6.3. Financial Overview
6.4. Treatment Type Benchmarking
6.5. Company Market Share Analysis, 2023
6.6. Strategy Mapping
6.7. Company Profiles
6.7.1. Bausch Health Companies Inc.
6.7.1.1. Company overview
6.7.1.2. Financial performance
6.7.1.3. Product benchmarking
6.7.1.4. Strategic initiatives
6.7.2. Almirall, S.A.
6.7.2.1. Company overview
6.7.2.2. Financial performance
6.7.2.3. Product benchmarking
6.7.2.4. Strategic initiatives
6.7.3. Genentech, Inc. (Subsidiary of F. Hoffmann-La Roche AG)
6.7.3.1. Company overview
6.7.3.2. Financial performance
6.7.3.3. Product benchmarking
6.7.3.4. Strategic initiatives
6.7.4. Novartis AG.
6.7.4.1. Company overview
6.7.4.2. Financial performance
6.7.4.3. Product benchmarking
6.7.4.4. Strategic initiatives
6.7.5. Regeneron Pharmaceuticals Inc.
6.7.5.1. Company overview
6.7.5.2. Financial performance
6.7.5.3. Product benchmarking
6.7.5.4. Strategic initiatives
6.7.6. Dr Reddy’s Laboratories.
6.7.6.1. Company overview
6.7.6.2. Financial performance
6.7.6.3. Product benchmarking
6.7.6.4. Strategic initiatives
6.7.7. Taro Pharmaceuticals Ltd.
6.7.7.1. Company overview
6.7.7.2. Financial performance
6.7.7.3. Product benchmarking
6.7.7.4. Strategic initiatives
6.7.8. Accord Healthcare Limited (Subsidiary of Intas Pharmaceuticals)
6.7.8.1. Company overview
6.7.8.2. Financial performance
6.7.8.3. Product benchmarking
6.7.8.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America basal cell carcinoma market, by region, 2018-2030 (USD Million)
Table 3 North America basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 4 U.S. basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 5 Canada basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 6 Mexico basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 7 Europe basal cell carcinoma market, by region, 2018-2030 (USD Million)
Table 8 Europe basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 9 Germany basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 10 UK basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 11 France basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 12 Italy basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 13 Spain basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 14 Denmark basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 15 Sweden basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 16 Norway basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 17 Asia Pacific basal cell carcinoma market, by region, 2018-2030 (USD Million)
Table 18 Asia Pacific basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 19 China basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 20 Japan basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 21 India basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 22 South Korea basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 23 Australia basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 24 Thailand basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 25 Latin America basal cell carcinoma market, by region, 2018-2030 (USD Million)
Table 26 Latin America basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 27 Brazil basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 28 Argentina basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 29 MEA basal cell carcinoma market, by region, 2018-2030 (USD Million)
Table 30 MEA basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 31 South Africa basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 32 Saudi Arabia basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 33 UAE basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
Table 34 Kuwait basal cell carcinoma market, By treatment type, 2018-2030 (USD Million)
List of Figures
Figure 1 Basal cell carcinoma treatments market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Value chain-based sizing & forecasting
Figure 6 QFD modelling for market share assessment.
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Treatment type segment snapshot
Figure 10 Competitive landscape snapshot
Figure 11 Parent market (USD Billion)
Figure 12 Market dynamics
Figure 13 Porter’s five forces analysis
Figure 14 PESTLE analysis
Figure 15 Basal cell carcinoma treatment market: Treatment type outlook key takeaways
Figure 16 Basal cell carcinoma treatment market: Treatment type movement analysis
Figure 17 Surgery market estimates and forecasts, 2018-2030 (USD Million)
Figure 18 Mohs surgery market estimates and forecasts, 2018-2030 (USD Million)
Figure 19 Tumor removal procedures (including skin cancer)
Figure 20 Surgical excision market estimates and forecasts, 2018-2030 (USD Million)
Figure 21 Electrodesiccation and Curettage (ED&C) market estimates and forecasts, 2018-2030 (USD Million)
Figure 22 Radiotherapy market estimates and forecasts, 2018-2030 (USD Million)
Figure 23 Intralesional injections market estimates and forecasts, 2018-2030 (USD Million)
Figure 24 Topical chemotherapy market estimates and forecasts, 2018-2030 (USD Million)
Figure 25 5-fluorouracil (5-FU) market estimates and forecasts, 2018-2030 (USD Million)
Figure 26 Tirbanibulin (Klisyri) market estimates and forecasts, 2018-2030 (USD Million)
Figure 27 Imiquimod (Zyclara) market estimates and forecasts, 2018-2030 (USD Million)
Figure 28 Oral medications market estimates and forecasts, 2018-2030 (USD Million)
Figure 29 Vismodegib (Erivedge) market estimates and forecasts, 2018-2030 (USD Million)
Figure 30 Sonidegib (Odomzo) market estimates and forecasts, 2018-2030 (USD Million)
Figure 31 Intravenous medications market estimates and forecasts, 2018-2030 (USD Million)
Figure 32 Chemical peeling treatment minimally invasive procedures, 2018-2030 (USD Million)
Figure 33 Chemical peeling treatment market estimates and forecasts, 2018-2030 (USD Million)
Figure 34 Basal cell carcinoma treatment market revenue, by region, 2023 & 2030 (USD Million)
Figure 35 Regional marketplace: Key takeaways
Figure 36 Regional marketplace: Key takeaways
Figure 37 North America basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 38 Key country dynamics
Figure 39 U.S. basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 40 Key country dynamics
Figure 41 Canada basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 42 Key country dynamics
Figure 43 Mexico basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 44 Regulatory framework
Figure 45 Europe basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 46 Key country dynamics
Figure 47 UK basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 48 Key country dynamics
Figure 49 Germany basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 50 Key country dynamics
Figure 51 France basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 52 Key country dynamics
Figure 53 Spain basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 54 Key country dynamics
Figure 55 Italy basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 56 Key country dynamics
Figure 57 Denmark basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 58 Key country dynamics
Figure 59 Sweden basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 60 Key country dynamics
Figure 61 Norway basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 62 Rest of Europe basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 63 Asia Pacific basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 64 Key country dynamics
Figure 65 Japan basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 66 Japan pharmaceutical registration
Figure 67 Key country dynamics
Figure 68 China basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 69 Regulatory details: China
Figure 70 Key country dynamics
Figure 71 India basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 72 Registration details: India
Figure 73 Key country dynamics
Figure 74 Australia basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 75 Drug pricing: Australia
Figure 76 Contribution of PBS by disease
Figure 77 Key country dynamics
Figure 78 Thailand basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 79 Key country dynamics
Figure 80 South Korea basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 81 Reimbursement scenario: South Korea
Figure 82 Rest of Asia Pacific basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 83 Latin America basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 84 Key country dynamics
Figure 85 Brazil basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 86 Key country dynamics
Figure 87 Argentina basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 88 Argentina pharmaceuticals registration details
Figure 89 Argentina pharmaceuticals reimbursement details
Figure 90 Rest of Latin America basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 91 MEA basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 92 Key country dynamics
Figure 93 South Africa basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 94 Regulatory framework: South Africa
Figure 95 Regulatory framework: South Africa drug registration fees
Figure 96 Key country dynamics
Figure 97 Saudi Arabia basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 98 Key country dynamics
Figure 99 UAE basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 100 Key country dynamics
Figure 101 Kuwait basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 102 Regulatory framework: Kuwait
Figure 103 Rest of MEA basal cell carcinoma treatment market estimates and forecast, 2018-2030 (USD Million)
Figure 104 Market participant categorization
Figure 105 Heat map analysis
Figure 106 Strategic framework

Companies Mentioned

  • Bausch Health Companies Inc.
  • Almirall, S.A.
  • Genentech, Inc. (Subsidiary of F. Hoffmann-La Roche AG)
  • Novartis AG.
  • Regeneron Pharmaceuticals Inc.
  • Dr Reddy’s Laboratories.
  • Taro Pharmaceuticals Ltd.
  • Accord Healthcare Limited (Subsidiary of Intas Pharmaceuticals)

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages158
PublishedJune 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 2.96 Billion
Forecasted Market Value ( USD ) by 2030 $ 5.93 Billion
Compound Annual Growth Rate10.4%
Regions CoveredGlobal
No. of Companies Mentioned8

Related Topics

Related Reports

Basal Cell Carcinoma Treatment Market by Type, Route of Administration, Clinical Variant, End-Users - Global Forecast 2025-2030 - Product Image

Basal Cell Carcinoma Treatment Market by Type, Route of Administration, Clinical Variant, End-Users - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Basal Cell Carcinoma (Basal Cell Epithelioma) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Basal Cell Carcinoma (Basal Cell Epithelioma) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Nevoid Basal Cell Carcinoma Syndrome (NBCCS) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Nevoid Basal Cell Carcinoma Syndrome (NBCCS) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Basal Cell Carcinoma Treatment Market Analysis & Forecast to 2024-2034 - Product Image

Basal Cell Carcinoma Treatment Market Analysis & Forecast to 2024-2034

  • Report
  • 200 Pages
  • Global
From
Basal Cell Carcinoma Treatment Global Market Report 2024 - Product Image

Basal Cell Carcinoma Treatment Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.